Robert Baffi - BioMarin Pharmaceutical Insider

BioMarin Pharmaceutical -- USA Stock  

USD 81.13  0.95  1.16%

Executive VP of Technical Operations

Dr. Robert A. Baffi, Ph.D., serves as an Executive Vice President Technical Operations of Biomarin Pharmaceutical Inc. From 2000 to December 2009, Dr. Baffi served as our Senior Vice President of Technical Operations. From 1986 to 2000, Dr. Baffi served in a number of increasingly responsible positions at Genentech, Inc., primarily in the functional area of quality control. Prior to Genentech, Dr. Baffi worked for Cooper BioMedical as a Research Scientist and at Becton Dickinson Research Center as a PostDoctoral Fellow. Dr. Baffi has contributed to more than 20 regulatory submissions for product approval in the United States and Europe and to more than 50 regulatory submissions for investigational new drug testing. He currently serves on the board for the National Institute for Bioprocessing Research Training
Age: 61  EVP Since 2009  MBA    
415-506-6700  http://www.biomarin.com
Baffi received a Ph.D., M. Phil and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

Robert Baffi Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (1.78) % which means that it has lost $1.78 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (4.2) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 1.17 B in liabilities with Debt to Equity (D/E) ratio of 41.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioMarin Pharmaceutical has Current Ratio of 2.65 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was founded in 1996 and is headquartered in San Rafael, California. BioMarin Pharmaceutical operates under Biotechnology classification in USA and traded on NASDAQ. It employs 2581 people.BioMarin Pharmaceutical (BMRN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 2,581 people. BioMarin Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.

BioMarin Pharmaceutical Leadership Team

Elaine Heron, Director, MBA
Dennis Slamon, Director, Ph.D
Henry Fuchs, President, Ph.D
Robert Hombach, Director, MBA
Brian Mueller, VP
Bryan Lawlis, Director, Ph.D
JeanJacques Bienaime, Chairman, MBA
Jeff Ajer, President, MBA
Richard Meier, Director
Willard Dere, Director
Daniel Spiegelman, President, MBA
Kathryn Falberg, Director, MBA
Eric Davis, SVP
Pierre Lapalme, Chairman
Robert Baffi, EVP, MBA
Alan Lewis, Director, Ph.D
Richard Ranieri, President
David Pyott, Director, MBA
Michael Grey, Director

Stock Performance Indicators

Did you try this?

Run Watchlist Optimization Now
   

Watchlist Optimization

Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
View All  Next Launch Watchlist Optimization

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Check also Trending Equities. Please also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .